Efficacy of recombinant bovine interleukin-2 as an adjunct to dry cow therapy.
Recombinant bovine interleukin-2 was tested as adjunct therapy to intramammary infusion of antibiotics at drying off. Cows were assigned randomly within three commercial herds to either recombinant bovine interleukin-2 or PBS treatment groups at drying off. Ninety-five cows received intramammary infusions of 1 mg of recombinant bovine interleukin-2 in each quarter immediately preceding intramammary infusion of a product for antibiotic therapy of dry cows. Ninety-four cows received intramammary infusion of 10 ml of endotoxin-free PBS in each quarter immediately preceding the antibiotic therapy. Cure rates for IMI present at drying off did not differ between cows treated with recombinant bovine interleukin-2 and those treated with PBS. Intramammary infusion of recombinant bovine interleukin-2 did not affect the rate of new IMI during the dry period. Milk production and SCC during the first 3 mo of lactation subsequent to therapy did not differ between treatment groups. Intramammary infusion of recombinant bovine interleukin-2 was not effective as an adjunct to antibiotic therapy for dry cows.
Hogan
J S
JS
Department of Dairy Science, Ohio State University, Ohio Agricultural Research and Development Center, Wooster 44691, USA.
Smith
K L
KL
Todhunter
D A
DA
Schoenberger
P S
PS
Shuster
D
D
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002417:Cattle; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008321:Mammary Glands, Animal; D008414:Mastitis, Bovine / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D007376:Interleukin-2; D011994:Recombinant Proteins